NCT02283840View on ClinicalTrials.gov

Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Epilepsy
Interventions
DRUG

BIA 2-093

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT02283840 - Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation | Biotech Hunter | Biotech Hunter